Epigenetics Market

Market Snapshot

Forecast Years for Epigenetics Market:	2022 - 2028
Historical Years for Epigenetics Market:	2016 - 2021
Revenue 2021 for Epigenetics Market:	USD 0.8 Billion
Revenue 2028 for Epigenetics:	USD 3.0 Billion
Revenue CAGR (2022 - 2028) for Epigenetics Market :	13.1%
Fastest Growing Region (2022 - 2028) for Epigenetics Market:	Asia Pacific
Largest Region (2021) for Epigenetics Market:	North America

Market Synopsis:

Global Epigenetics market is valued at USD 0.8 Billion in 2021 and is projected to attain a value of USD 3.0 Billion by 2028 at a CAGR of 13.1% during the forecast period, 2022–2028. The increased prevalence of cancer and other chronic diseases, as well as the ageing population, are expected to drive market expansion. The presence of institutions like the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) is helping the industry flourish. These groups advocate for funding and support for Epigenetics -related R&D and product development. The National Institutes of Health has a common fund epigenomics initiative that actively encourages innovative Epigenetics research around the world.

COVID-19's increased prevalence is expected to have an impact on market growth over the projection period. The COVID-19 dilemma has had a significant and immediate impact on the healthcare industry. Because of the unexpected impact on the supply chain and the limits imposed on manufacturing and supply operations during the early stages of the Corona virus pandemic, most pharmaceutical and nutraceutical companies suffered a minor loss in the first few quarters. COVID-19, on the other hand, has raised demand for Epigenetics, and some important players have seen favorable sales growth as a result of the increased demand.

Rising Cancer Prevalence

There has been a huge increase in the number of people diagnosed with cancer around the world. According to WHO forecasts, the number of cancer patients is predicted to rise from 14.1 million in 2012 to 19.3 million by 2025. Cancer formation and progression are linked to Epigenetics, alterations such as DNA methylation dysregulation. Epigenetics opens up new avenues for developing therapeutic treatments to counteract cancer deregulation. Several cancer research studies using Epigenetics, approaches are now underway, and significant funding is being allocated to these investigations.

High Cost of Instruments

Instruments necessary for epigenetics research are costly since they have advanced features and functions. The NovaSeq 5000 and 6000 sequencers from Illumina, for example, are priced at USD 850,000 and USD 985,000, respectively, and were released in January 2017. Maintenance and a variety of additional indirect costs, such as samples and consumables, add to the overall cost of ownership. Many of these systems are required by pharmaceutical corporations and research institutes. As a result, large sums of money will be needed to purchase a number of high-priced genomic devices. End users with limited budgets, such as academic research laboratories, find it challenging to afford such systems. As a result of the high costs of instruments, their widespread acceptance is hampered, which is projected to limit market growth over the projection period.

Market Segmentation:

The Global Epigenetics Market can be segmented by product type, into Reagents & Kits, Instruments and Others. By Application into Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases, and Others. Based on Technology into DNA Methylation, Histone Methylation, Histone Acetylation, Large non - coding RNA, MicroRNA modification, Chromatin structures. Based on Region, the Market is segmented into North America, Europe, Asia Pacific, Latin America And Middle East & Africa.

North America to Continue Dominating the Epigenetics Market

With a market share of around 40% in 2021, North America was at the forefront of the market. Governments in the region are supporting ongoing Epigenetics research by providing financing. Aside from that, the existence of superior healthcare facilities and ongoing advances in diagnostic methods are boosting the regional market's growth. The expanding elderly population and high acceptance of technologically improved facilities are expected to drive the market in North America.

Key Players:

Some of the players are Illumina (US), Thermo Fisher Scientific (US), Merck Millipore (US), Abcam (UK), Active Motif (US), Bio-Rad Laboratories (US), New England Biolabs (US), Agilent (US), QIAGEN (Netherlands), Zymo Research (US), PerkinElmer (US), and Diagenode (Belgium).

The Epigenetics market is segmented as follows:

Parameter	Details
Segments Covered	Product (Instruments, Reagents & Kits, Others) Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases, Others) Technology (Methylation, Acetylation, Phosphorylation, Other Technologies) Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Regions & Countries Covered	North America - (U.S., Canada, Mexico) Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe) Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific) Latin America - (Brazil, Argentina, Rest Of Latin America) Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered	Illumina (US) Thermo Fisher Scientific (US) Merck Millipore (US) Abcam (UK) Active Motif (US) Bio-Rad Laboratories (US) New England Biolabs (US) Agilent (US) QIAGEN (Netherlands) Zymo Research (US) PerkinElmer (US) and Diagenode (Belgium) are the major companies operating in Epigenetics Market.
Report Coverage	Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

Epigenetics Market is tabulated as follows: